LAURUSLABS Q2 FY27 Earnings Call: Record Revenue Hits Rs. 2,206 Cr, Small Molecule CDMO Grows 86%

LAURUSLABS held its Q2 FY27 earnings call on October 29, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Record Quarter on CDMO Strength and Affordable Medicines Momentum

• Record revenue of Rs.2,206 crore in Q2 FY 2026-2027 — the highest quarterly income from operations to date, driven by CDMO platform strength, growing commercial-based supplies, and affordable medicines momentum; H1 FY 2026-2027 total income stood at Rs.4,233 crore, up 31%.
• EBITDA of Rs.762 crore at 34.5% margin in Q2 FY 2026-2027 — up 2.7 percentage points versus prior quarters and flagged by an analyst as the highest ever; H1 FY 2026-2027 EBITDA was Rs.1,406 crore at 33.2%.
• PAT of Rs.441 crore in Q2 FY 2026-2027 — Rs.809 crore for H1 FY 2026-2027; ROCE improved to 22.5% for H1 FY 2026-2027 versus 17.7% in FY26.
• Gross margin held at ~63% in Q2 FY 2026-2027 (62.9% for H1 FY 2026-2027), aided by product/division mix and operational efficiencies.
• Net debt of Rs.2,466 crore as of Q2 FY 2026-2027 — debt-to-EBITDA at ~1.02 versus 1.28 in Q1 FY 2026-2027, on strong internal cash flows.
• Sequential revenue increase of Rs.200 crore from Q1 FY 2026-2027 to Q2 FY 2026-2027 — CDMO contributed only Rs.40 crore while Affordable Medicines added Rs.160 crore, per the CFO.
• Capex of ~Rs.470 crore in Q2 FY 2026-2027 and Rs.864 crore in H1 FY 2026-2027; operating cash flow fell 26% in H1 FY 2026-2027 and free cash flow turned slightly negative after capex, which the CFO linked to regular inventory to be utilized in Q3 and Q4 FY 2026-2027.

Small Molecule CDMO Grows 86%; LaurusBio in Transition

• Small molecule CDMO grew 86% YoY with Rs.875 crore sales in Q2 FY 2026-2027 — H1 FY 2026-2027 revenue of Rs.1,710 crore, ~77% growth, driven by late-stage program deliveries and commercial API supplies to global partners.
• Affordable medicines revenue of Rs.1,302 crore in Q2 FY 2026-2027, up 15% YoY — H1 FY 2026-2027 growth of 13% on order book expansion and stable pricing; ARV API at Rs.625 crore and ARV FDF at Rs.677 crore in Q2 FY 2026-2027.
• LaurusBio sales of Rs.29 crore in Q2 FY 2026-2027 and Rs.64 crore in H1 FY 2026-2027 — down 16% against the ~Rs.200 crore base cited in July 2026; CEO attributed the decline to customer allocations and projects scaling up on both sides, with campaign phasing cited for YoY variation.
• Laurus Bio 4 facility to be qualified in Q3 FY 2026-2027 — only trials in Q4 FY 2026-2027, with actual commercial supplies possibly starting Q1 FY 2027-2028; customer capacity reservations already advancing.
• ~125 active CDMO projects as of the Q2 FY 2026-2027 call — management declined to update the count further; no significant customer or program concentration across the ~100-120 customer base, attributed to how projects came rather than deliberate management.
• Order visibility for the next 18-24 months — management does not foresee significant destocking events, and CDMO programs supported face no patent cliff; CDMO growth expected to remain "pretty consistent" with no Q2 one-offs.
• Crop science remains minuscule versus human and animal health initiatives in H1 FY 2026-2027, though discussions with several partners continue and management hopes for meaningful contribution (period unspecified).

Aggressive Peptide Build-Out; Oligo and Resin Acquisitions

• SPPS peptide reactor volume exceeds 16,000 liters after commissioning a commercial-scale peptide block in Q2 FY 2026-2027; capacity covers the full value chain — synthesis, purification and isolation — with significant further expansions planned (period unspecified).
• Peptide validation batches could begin in 12-18 months from the call date — roughly Q3 FY 2027-2028 through Q1 FY 2028-2029 — per CDMO head Krishna Chaitanya Chava, who said clinical timelines can move around but "this number can be assumed."
• Commercial peptide revenues expected in FY 2028-2029 — Krishna Chaitanya Chava said commercial revenues from some peptide capacities are expected in FY29, with asset utilization expected to be fairly high even during validation campaigns in the interim.
• Two acquisitions announced in Q2 FY 2026-2027 — a 60% majority stake in Canada-based Galena Sciences (oligonucleotides, precision magnetic nanoparticle purification; currently no customer) and a majority stake in Hyderabad-based SIMC Resins (peptide resins, chromatography stationary phases); management said the resins investment is not expected to deliver much financial benefit but strengthens peptide positioning.
• GLP-1 ambition — on peptide GLP-1 contracts over the next 5 years, Krishna Chaitanya Chava said, given capabilities and capacities being invested in, he "certainly expects" to play a "very meaningful role" in that opportunity; management declined to comment on involvement in existing approved peptide GLP-1 products.
• Oligo scale caution — CEO said the oligo bet is "not same, but maybe similar" to the ARV playbook, and he does not expect oligos to reach ARV level within the next 4-5 years (through ~FY 2031-32); the investment was made because customers are asking for it.
• Capability envelope — Laurus covers all modalities except MAPS, cephalosporins, penicillins and monoclonal antibodies; an OEB5 facility for payload-linker work was commercialized as of Q2 FY 2026-2027; a 500,000L food-grade/industrial-grade fermentation facility (non-GMP) will be operational in Q3 FY 2026-2027, and a GMP-grade fermentation facility for select animal health products in H2 FY 2027-2028.

Rs.3,000 Crore Program On Track; Margin Commitments Reiterated

• Rs.3,000 crore capex guidance reaffirmed across FY 2026-27 and FY 2027-28 — most investments on track despite a lower H1 FY 2026-27 run-rate; beyond FY 2027-28, capex is expected at around Rs.1,500 crore per year, which may go up if opportunities arise.
• Margin guidance for FY 2026-2027 reiterated — over 60% gross margin and over 30% EBITDA margin; the CEO committed to maintaining 60+% gross margin and 30+% EBITDA margin (period unspecified) but declined to give revenue guidance.
• EBITDA bridge — CFO attributed the QoQ margin improvement to R&D cost normalization (Q1 FY27 costs were elevated due to ANDA filings, not a refocusing of R&D) and operating leverage from Rs.200 crore of incremental revenue; R&D spend was 4.3% of sales in H1 FY 2026-2027, up over 34% YoY, driven by gene therapy ADC technology infrastructure.
• Asset turn at 1x currently versus a 6-year average of 1.1x — management's first target is 1.1x, with the CFO saying asset turn could "inch towards" the historical peak of 1.4x but explicitly not committing to reaching it (period unspecified).
• Free cash flow trade-off acknowledged — the CFO said the company has taken a call between free cash flow versus growth capital and is investing growth capex, with net debt/EBITDA at a healthy ~1x as of Q2 FY 2026-2027.
• Domestic sales likely below 20% of total sales in Q2 FY 2026-2027 — sequential constant-currency impact was not significant at about Rs.12 crore; brownfield capex in Unit 4 and Unit 2 is ongoing in FY 2026-2027.

Karka and KRKA Timelines; Withheld Granularity a Recurring Theme

• Karka JV phase one production blocks to commence operations in mid-2027 — focused on high potent and general OSD manufacturing; management gave no quantified FDF revenue outlook for the 1-2 year horizon once Karka becomes live.
• KRKA JV product validations to begin mid-2027 — followed by regulatory filings, with management expecting meaningful revenue contribution in FY 2028-29.
• Affordable medicines expected to keep growing from Q3 FY 2026-2027 onward — H1 FY 2026-27 revenue around Rs.1,300 crore with a sharp Q2 uptick, driven by product registrations in multiple countries; API prices have stabilized despite geopolitical pressure.
• 92 DMFs filed cumulatively as of Q2 FY 2026-2027 — 2 developed-market dossiers filed and 2 approvals received in H1 FY 2026-2027; cumulative product filings stand at 96.
• Management repeatedly withheld granularity — declining peptide capex/gross block, commercialized molecule counts, human vs animal health CDMO split, and peptide capacity commitment levels, citing confidentiality; the CEO noted project values range from $200,000 to several tens of millions of dollars, so counts do not translate into revenue visibility.
• Small molecule CDMO launch lever unquantified — several programs remain at the NDA filing stage from the program flagged in Q1 FY 2026-2027; management declined to quantify contribution to the larger revenue base.
• Geopolitics declined — Krishna Chaitanya Chava declined to comment on industry-level implications of China's ban on technology exports and the US ban on investments in Chinese biotech.

Clean Audit Record; R&D Step-Up Tied to New Modalities

• 59 quality audits cleared in H1 FY 2026-2027 without any critical findings — by multiple regulatory agencies and key partners.
• R&D spend up over 34% YoY in H1 FY 2026-2027 — an exceptionally high increase driven primarily by capability development for gene therapy ADC technology infrastructure; ADC programs are not expected to reach multi-metric-ton volumes but commercial-stage value contribution is expected to be quite significant, with sizable associated investment.
• SBTi-validated near-term GHG reduction targets — management is making operational progress, with continued recognition from leading global ESG rating agencies.
• Supply chain reliability maintained — highly reliable delivery performance for all global partners despite heightened global volatility.
• Capability-led growth narrative — CEO attributed ~4x CDMO growth since April 2023 to technical capabilities (commercial-scale biocatalysis in 2021, then flow chemistry, flow hydrogenation, fermentation) rather than reactor volume alone; management stated it will not take on more than it can handle so as not to spoil partnerships.